Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Benefits Pro5d
Eli Lilly expands access to weight loss drug Zepbound
Eli Lilly headquarters located in Indianapolis, Indiana. Although the GLP-1 drug Zepbound has been shown to be effective ...
USA Today18d
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said on Wednesday patients ... while Wegovy led to a 15% weight loss after 68 weeks. Doctors had been prescribing these drugs based on whichever was available to patients at the ...